Psen1 Mutations In Alzheimer'S Disease plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Psen1 Mutations In Alzheimer'S Disease represents an important genetic factor in neurodegenerative disease research. This page provides comprehensive information about its role in disease mechanisms, genetic associations, and therapeutic implications.
Presenilin 1 (PSEN1) is the most common cause of autosomal dominant familial Alzheimer's disease, with over 200 pathogenic mutations identified. PSEN1 encodes the catalytic subunit of γ-secretase, and mutations alter amyloid-beta production.
- Gene: PSEN1 (Presenilin 1)
- Chromosome: 14q24.3
- Mutations: >200 pathogenic variants identified
- Inheritance: Autosomal dominant
- Prevalence: ~30-50% of all familial AD cases
Presenilin 1 is the catalytic core of γ-secretase:
- Proteolytic cleavage: Cuts APP at multiple sites within the transmembrane domain
- Aβ generation: Produces Aβ40 (∼90%) and Aβ42 (∼10%)
- Notch signaling: Essential for Notch receptor cleavage
- Aβ42/Aβ40 ratio: Most PSEN1 mutations increase the Aβ42/Aβ40 ratio
- Total Aβ: Some mutations increase, others decrease production
- Aβ42: More aggregation-prone, forms seeds more readily
- γ-secretase dysfunction: Altered cleavage specificity
- Aβ42 elevation: Increases amyloid nucleation
- Calcium dysregulation: ER calcium homeostasis disrupted
- Protein folding stress: Loss of presenilin function
- Tau pathology: Enhanced phosphorylation and aggregation
| Mutation |
Age of Onset |
Aβ Effect |
| M146L |
~45 years |
Aβ42 ↑ |
| L286V |
~50 years |
Aβ42 ↑↑ |
| A246E |
~50 years |
Aβ42 ↑ |
| H163R |
~55 years |
Aβ42 ↑ |
| A431V |
~55 years |
Aβ42 ↑ |
- PSEN1 M146L
- PSEN1 L250S
- PSEN1 P264L
- Range: 30-70 years (most commonly 45-55)
- Anticipation: Earlier onset in subsequent generations (anticipation)
- Memory impairment: Prominent early feature
- Progression: Often rapid once symptoms begin
- Behavioral changes: Early personality changes
- Myoclonus: Common in early-onset cases
- Seizures: More frequent than late-onset AD
- Amyloid plaques: Abundant Aβ42 deposition
- Neurofibrillary tangles: Severe tau pathology
- Cerebral amyloid angiopathy: Present in some mutations
- Neuronal loss: Hippocampus and cortex
- Early-onset AD (< 60 years)
- Autosomal dominant family history
- Atypical presentations
- Pathogenic mutations: Confirm diagnosis, inform family
- Variants of uncertain significance: Require careful interpretation
- Penetrance: Near 100% by age 80
- γ-secretase modulators: Shift cleavage away from Aβ42
- Aβ42 antibodies: May be particularly effective
- Anti-aggregation drugs: Target toxic Aβ species
Psen1 Mutations In Alzheimer'S Disease plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Psen1 Mutations In Alzheimer'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Ryman DC, et al. (2015). Symptomatic and preventive therapy in dominantly inherited Alzheimer's disease. Neurology.
- Wu L, et al. (2014). PSEN1 mutations in familial Alzheimer's disease. Molecular Neurobiology.
- Jayadev S, et al. (2010). Presenilin mutations and Alzheimer's disease. Cold Spring Harbor Perspectives in Medicine.